Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q2 EPS of ($0.42), $0.09 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $30.9 million versus the consensus estimate of $29.09 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.